
Please try another search
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
James J. Collins | 58 | 2021 | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director |
Timothy K. Lu | 43 | 2016 | Co-Founder, CEO & Director |
Brenda G. Cooperstone | 59 | 2019 | Independent Director |
Edward T. Mathers | 64 | 2016 | Independent Director |
Frances Schulz | - | 2024 | Director |
Robin G. Taylor | - | 2021 | Member of Scientific Advisory Board |
Lawrence Fong | - | - | Member of Scientific Advisory Board |
Ahmad Khalil | - | - | Member of Scientific Advisory Board |
Michael Andreeff | - | - | Member of Scientific Advisory Board |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Martin Fussenegger | - | - | Member of Scientific Advisory Board |
Michael D. Varney | 66 | 2021 | Member of Scientific Advisory Board |
Donald F. Tang | 41 | 2024 | Director |
Feng Hsiung | 50 | 2025 | Independent Director |
Wilson Wong | - | - | Scientific Co-Founder & Member of Scientific Advisory Board |
Bryan Daniel Baum | - | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review